Key result
Oral administration of cilostazol significantly improved right ventricular systolic function (TAPSE 2.2 vs 1.9 cm, P<0.001) and reduced pulmonary artery pressure (36.6 vs 39.9 mmHg, P=0.001).
Why the study?
Does oral cilostazol improve right ventricular function and reduce pulmonary artery pressure in patients with normal ejection fraction and mild to moderate pulmonary hypertension?
Observational (n=40)
Does oral cilostazol improve right ventricular function and reduce pulmonary artery pressure in patients with normal ejection fraction and mild to moderate pulmonary hypertension?
Absolute Event Rate: 2.2% vs 1.9%
p-value: p=< 0.001
Oral cilostazol improves right ventricular systolic function and reduces pulmonary artery pressure in patients with mild to moderate pulmonary hypertension.
INTRODUCTION: Cilostazol is a PDE3 inhibitor and used to treat peripheral arterial disease. There are few reports on the influence of cilostazol on heart. AIMS: The aim of this study was to assess this effect on right ventricular function and pulmonary artery pressure. METHODS: Forty patients with normal left and right ventricular ejection fraction and mild or moderate pulmonary artery hypertension were enrolled in the study. Right ventricular function was assessed by tricuspid annular plane systolic excursion (TAPSE), fractional area change (FAC), tissue Doppler imaging (TDI), and two-dimensional speckle-tracking echocardiography (2D-STE) before and after oral administration of cilostazol. Also pulmonary artery pressure assessed before and after administration of cilostazol. RESULTS: After cilostazol administration, there were significant increases in the TAPSE (1.9 ± 0.3 cm vs. 2.2 ± 0.3 cm, P < 0.001). Peak longitudinal strain (-18.7 ± 4.5% vs. -21.3 ± 3.7%, P = 0.001), isovolumetric acceleration (IVA) (176.6 ± 62.7 cm/sec(2) vs. 200.6 ± 61.9 cm/sec(2) , P = 0.025), right ventricular FAC increased significantly (37.6 ± 8.0% vs. 41.5 ± 8.9%, P < 0.001). Pulmonary artery pressure decreased significantly (39.9 ± 7.9 vs. 36.6 ± 5.5 mmHg, P = 0.001) after cilostazol administration. CONCLUSION: Our study demonstrated that cilostazol improved right ventricular systolic function and reduced pulmonary artery pressure.
No takes yet. Share an insight, caveat, or question.
Şahin et al. (2013) conducted an observational in mild or moderate pulmonary artery hypertension (n=40). Cilostazol vs. baseline was evaluated on tricuspid annular plane systolic excursion (TAPSE) (p=< 0.001). Oral administration of cilostazol significantly improved right ventricular systolic function (TAPSE 2.2 vs 1.9 cm, P<0.001) and reduced pulmonary artery pressure (36.6 vs 39.9 mmHg, P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: